Second Line Capital, LLC Viking Therapeutics, Inc. Transaction History
Second Line Capital, LLC
- $367 Billion
- Q3 2024
A detailed history of Second Line Capital, LLC transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Second Line Capital, LLC holds 38,118 shares of VKTX stock, worth $1.96 Million. This represents 0.66% of its overall portfolio holdings.
Number of Shares
38,118
Previous 28,419
34.13%
Holding current value
$1.96 Million
Previous $1.51 Billion
60.19%
% of portfolio
0.66%
Previous 0.46%
Shares
2 transactions
Others Institutions Holding VKTX
# of Institutions
473Shares Held
66.2MCall Options Held
5.72MPut Options Held
3.39M-
Vanguard Group Inc Valley Forge, PA10.2MShares$524 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.03MShares$311 Million0.01% of portfolio
-
State Street Corp Boston, MA4.67MShares$241 Million0.01% of portfolio
-
Jpmorgan Chase & CO New York, NY2.12MShares$109 Million0.01% of portfolio
-
Morgan Stanley New York, NY1.87MShares$96.6 Million0.01% of portfolio
About Viking Therapeutics, Inc.
- Ticker VKTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,688,496
- Market Cap $3.95B
- Description
- Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...